Mouse Genome Informatics
ht
    Trp53tm3.1Glo/Trp53+
B6.129S7-Trp53tm3.1Glo
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• heterozygous mutants die between 150 to750 days after birth, however this survival curve is no different from heterozygous Trp53 mice

tumorigenesis
• the osteosarcomas and carcinomas of heterozygous mutants metastasized when compared to heterozygous Trp53tm1Tyj mice
• 31.5% of heterozygous mutants developed lymphomas
• 15.5% of heterozygous mutants developed carcinomas, which are rare in homozygotes
• 53% of heterozygous mutants developed sarcomas

cellular
• higher DNA synthesis in MEFs with cells continuing to synthesize DNA between days 6 and 10 of culture compared to wildtype or heterozygous or homozygous Trp53tm1Tyj MEFs which reached a quiescent state at day 6 and did not reenter the cell cycle
• irradiated E13.5 heterozygous embryos showed no evidence of apoptosis in the hypothalamus compared to wildtype and heterozygous Trp53tm1Tyj mutants that showed a high number of apoptotic cells
• MEFs initially did not show any significant differences in growth rate but by day 4, grew more rapidly than wildtype or heterozygous or homozygous null Trp53tm1Tyj MEFs and reached a much higher saturation density

Mouse Models of Human Disease
OMIM IDRef(s)
Li-Fraumeni Syndrome 1; LFS1 151623 J:95318